Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Drops By 5.3%

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a large drop in short interest in May. As of May 31st, there was short interest totalling 3,960,000 shares, a drop of 5.3% from the May 15th total of 4,180,000 shares. Currently, 9.1% of the shares of the company are sold short. Based on an average daily volume of 927,200 shares, the days-to-cover ratio is presently 4.3 days.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Oppenheimer cut their target price on Astria Therapeutics from $29.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, May 21st. Jefferies Financial Group raised their price objective on shares of Astria Therapeutics from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 25th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Friday, May 10th. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a research report on Friday, May 10th.

Institutional Investors Weigh In On Astria Therapeutics

Large investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. raised its position in Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 2,861 shares during the last quarter. AJOVista LLC acquired a new position in Astria Therapeutics during the 4th quarter worth about $51,000. American International Group Inc. grew its holdings in Astria Therapeutics by 49.4% during the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock worth $346,000 after acquiring an additional 8,122 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in Astria Therapeutics in the 1st quarter valued at about $200,000. Finally, Jump Financial LLC bought a new position in shares of Astria Therapeutics in the third quarter worth about $111,000. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $8.99 on Wednesday. The company has a market capitalization of $493.64 million, a PE ratio of -3.88 and a beta of 0.79. The company’s fifty day moving average is $9.52 and its 200-day moving average is $10.47. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, analysts forecast that Astria Therapeutics will post -1.56 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.